National Access Cannabis, in collaboration with PhytoSciences Consulting, a U.S. company specializing in clinical trial design pertaining to medical cannabis, will be establishing the first two-year pharmacovigilance project to monitor outcomes and adverse events related to the use of cannabis for medical purposes in Canada. This project will provide important observational data to support future evidenced-based clinical trials.

National Access Cannabis in collaboration with PhytoSciences Consultants is launching the largest harm reduction study to date. The purpose of this international study is to investigate the potential use of cannabis as a substitute for prescription opiates. Patients will be followed by our research team over a two-year period and will participate in periodic scientific-based questionnaires administered by pharmacists.